Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Treating BRCA breast cancer with PARP inhibition

Dr Mika Sovak - AstraZeneca, Cambridge, UK

Treating BRCA breast cancer with PARP inhibition ( Dr Mika Sovak - AstraZeneca, Cambridge, UK )

Relieving spinal cord compression symptoms with a single radiation treatment

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom

Relieving spinal cord compression symptoms with a single radiation treatment ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )

Halving duration of ADT for high risk prostate cancer patients

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Halving duration of ADT for high risk prostate cancer patients ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

Findings of a phase I/II study of nivolumab in patients with virus-associated...

Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours ( Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France )

Selumetinib in children with recurrent or refractory low-grade glioma

Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago...

$Selumetinib in children with recurrent or refractory low-grade glioma ( Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA )$

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain

Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy

Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy ( Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy )

Expert prostate discussion: Clinical diagnostics, genomics, systemic and...

Dr Chris Parker and Prof Charles Ryan

Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiological treatment ( Dr Chris Parker and Prof Charles Ryan )

Web-based system for self-reporting symptoms may help patients live longer

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of...

Web-based system for self-reporting symptoms may help patients live longer ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

Olaparib slows growth of BRCA-related metastatic breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Olaparib slows growth of BRCA-related metastatic breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer